Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0TUJEV
ADC Name	Zt/g4-MMAE
Synonyms	Zt/g4 MMAE Click to Show/Hide
Drug Status	Investigative
Indication	In total 1 Indication(s) Pancreatic ductal adenocarcinoma [ICD11:2C10] Investigative
Drug-to-Antibody Ratio	4
	3D MOL	2D MOL
Antibody Name	Anti-RON Zt/g4 (IgG1 kappa)		Antibody Info
Antigen Name	Macrophage-stimulating protein receptor (MST1R)		Antigen Info
Payload Name	Monomethyl auristatin E		Payload Info
Therapeutic Target	Microtubule (MT)		Target Info
Linker Name	Mc-Val-Cit-PABC		Linker Info
Conjugate Type	Random conjugation through reduced inter-chain cysteines.
Combination Type	Vedotin

General Information of The Activity Data Related to This ADC

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 1 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Tumor Growth Inhibition value (TGI)	≈ 100	%	BxPC-3 cells	Pancreatic ductal adenocarcinoma

Full List of Activity Data of This Antibody-drug Conjugate

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100.00% (Day 40)	Positive RON expression (RON +++/++)
Method Description	Treatment began when tumors reached a mean tumor volume of 100 to 150 mm³. Zt/g4-MMAE or Zt/g4-DM1 at 20 mg/kg in a Q12 2 regimen was injected through the tail vein.
In Vivo Model	BxPC3 CDX model
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186

References

Ref 1	Preclinical Efficacy of Anti-RON Antibody-Drug Conjugate Zt/g4-MMAE for Targeted Therapy of Pancreatic Cancer Overexpressing RON Receptor Tyrosine Kinase. Mol Pharm. 2018 Aug 6;15(8):3260-3271. doi: 10.1021/acs.molpharmaceut.8b00298. Epub 2018 Jun 26.